Skip to main content

Pediatrics

Center for Pediatric Research

Clinical Trials

Showing 1-9 out of 54 results.
NCT03321734

YINTERMITTENT HYPOXIA AND CAFFEINE IN INFANTS BORN PRETERM

Icon for trial | R01HD089289 YINTERMITTENT HYPOXIA AND CAFFEINE IN INFANTS BORN PRETERM

This study is currently enrolling.

You are being asked to allow your baby to be in this research study because your premature baby was given the medication caffeine as treatment for his/her immature breathing in the neonatal intensive care unit (NICU). Particip ...

NCT03969992

A Partially-Blind, Randomized, Controlled, Parallel-Group Dose Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact (SF-RI 1 surfactant for inhalation combined with a dedicated drug delivery system) in Preterm Infant at Risk of Worsening Respiratory Distress Syndrome

Icon for trial | APC-AF-CLN-002 A Partially-Blind, Randomized, Controlled, Parallel-Group Dose Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact (SF-RI 1 surfactant for inhalation combined with a dedicated drug delivery system) in Preterm Infant

This study is currently enrolling.

The goal of this study is to see if giving surfactant as an aerosol to babies while they are on nCPAP or nIMV will decrease their need to be placed on a ventilator and receive surfactant through a breathing tube or through a ca ...

NCT03962543

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing or Causing Significant Morbidity

Icon for trial | MEK-NF-201 A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Progressing or Causing Significant Morbidity

This study is currently enrolling.

This research is conducted to study an investigational drug referred to as PD-0325901 (also known as mirdametinib) that has not been approved by the US Food and Drug Administration (FDA) or any other Regulatory Authority for th ...